A Phase 4 interventional study of Sufentanil and Sufentanil in Analgesia, Patient-Controlled, Gastrectomy and Arthroplasty, sponsored by Second Affiliated Hospital of Xi'an Jiaotong University. Status unknown. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2015-07-21.
Sponsored by Second Affiliated Hospital of Xi'an Jiaotong University · Phase 4, Interventional, and Treatment
Effective postoperative pain control is essential for patients and inadequate postoperative pain relief can cause mental and psychological sufferings. Despite the growing concern on postoperative pain management, acute postoperative pain is still poorly managed. Though numerous clinical practice guidelines for postoperative pain management have been published throughout the last decades, inadequate pain relief remain a big health care issue. Sufentanil has been used as satisfied pain control drug because of its strong potency of analgesia for a long while. But its use in patient controlled intravenous analgesia (PCIA) has not been clarified. And the dilemma of safety concern and insufficient dosage of analgesic is a common problem. Thus the investigators design this prospective randomized controlled double blinded trial to observe the efficacy and the optimal dose of sufentanil in PCIA in patients underwent moderate surgery for the purpose of providing reference in clinical practice.
Objective To explore the efficacy and the optimal dose of sufentanil in PCIA in patients underwent moderate surgery for the purpose of providing reference in clinical practice.
Methods 60 patients aging from 20 to 75，BMI 18 to 28 kg/m2，American Society of Anesthesiologists (ASA) grade I to II, anticipated surgery duration within 4 hrs and agreed to sign consent paper were scheduled for selective moderate surgery(including abdominal surgery and arthroplasty). Exclusive criteria: severe respiratory, cardiovascular or neurological disease, hepatic or renal dysfunction, psychiatric history or with unstable mental state, drug addiction or dependence. All patients were randomly assigned into 3 groups, S1 received 1.5 ug/kg sufentanil in PCIA, S2 received 2.0 ug/kg sufentanil, S3 received 2.5 ug/kg sufentanil. All patients received general anesthesia which was induced with midazolam 2mg, sufentanil 0.5ug/kg, propofol 2mg/kg, cisatracurium 0.2mg/kg and was maintained with continuous infusion of propofol, remifentanil and cisatracurium to maintain bispectral index (BIS) value between 40 and 60. Monitoring of MAP, heart rate (HR), pulse oxymetry (SpO2%), End-tidal CO2 (ETCO2), blood loss, and transfusion were recorded during anesthesia.
After patient waked, a loading dose of 10 ug sufentanil was given per time according to the patients' pain level and the loading dose was repeated till the pain relived or the RR was less than 10 times per min. Then the patient-controlled analgesia (PCA) pump was attached, and the continuous infusion speed was set at 2 ml/h. The pump was set to give an amount of 0.5ml at each press with a lockout interval of 10min. Patient was observed in the PACU for at least 30 min until the discharge criteria was reached. All the patients were followed-up at 2h, 6h, 24h and 48 h after the surgery. Clinical evaluations included MAP, HR, respiratory rate (RR), SpO2%, total pressing times, total amount of sufentanil, additional analgesic requirement, VAS, numerical rating scale (NRS) and Ramsey sedation scale were recorded. Side effects include nausea and vomiting, urinary retention, pruritus, respiratory depression were also recorded. Overall satisfaction index were inquired as well.
1,190 studies on the registry are indexed under Agnosia; 508 are open to participants now.
This study's planned enrollment of 60 is below the median of 78 across 1,024 interventional studies indexed under Agnosia.
Browse Agnosia studies →Second Affiliated Hospital of Xi'an Jiaotong University is the lead sponsor of 68 studies on the registry; 15 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Sufentanil,1.5mcg/kg
Drug: Sufentanil · Drug: Midazolam · Drug: propofol · Drug: cisatracurium
Sufentanil, 2.0mcg/kg
Drug: Sufentanil · Drug: Midazolam · Drug: propofol · Drug: cisatracurium
Sufentanil, 2.5mcg/kg
Drug: Sufentanil · Drug: Midazolam · Drug: propofol · Drug: cisatracurium
low dose
Also known as: Renfu Pharmacy
moderate dose
Also known as: Renfu Pharmacy
high dose
Also known as: Renfu Pharmacy
Midazolam 2 mg, sufentanil 0.5 mcg/kg, propofol 2 mg/kg, cisatracurium 2 mg/kg for induction, continuous infusion of propofol, remifentanil and cisatracurium to maintain bispectral index (BIS) value between 40 and 60 for maintenance.
Change of Pain on the VAS scale after surgery
Time frame: 2, 6, 24 and 48hrs after surgery
Change of Pain on the NRS scale after surgery
Time frame: 2, 6, 24 and 48hrs after surgery
No study locations are listed for this record.
This study is status unknown, as verified in Jul 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Second Affiliated Hospital of Xi'an Jiaotong University